<DOC>
	<DOCNO>NCT00002714</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy plus radiation therapy treat patient early stage Hodgkin 's disease .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Early-Stage Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine progression-free overall survival 5 10 year short-term Stanford V regimen comprise mechlorethamine , doxorubicin , vinblastine , prednisone , vincristine , bleomycin , etoposide follow modified involved-field radiotherapy patient favorable , early-stage Hodgkin 's disease . II . Determine whether early late toxic effect treatment minimize avoid stag laparotomy , limit cumulative dos chemotherapeutic drug , reduce dose volume radiotherapy patient . III . Determine freedom second disease progression 5 10 year treatment treatment-related toxicity patient . IV . Determine quality life patient treat regimen . OUTLINE : Patients receive Stanford V regimen comprise mechlorethamine IV day 1 29 ; doxorubicin IV vinblastine IV day 1 , 15 , 29 , 43 ; oral prednisone every day day 1-36 follow tapered dos ; vincristine IV bleomycin IV day 8 , 22 , 36 , 50 ; etoposide IV day 15 , 16 , 43 , 44 . Beginning 2 week completion chemotherapy blood count recover , patient undergo modify involved-field radiotherapy 5 day week 3-4 week . Quality life assess . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIIA Hodgkin 's disease No lymphocyte predominant disease No stage IA high neck presentation ( top larynx ) No mediastinal mass equal great onethird maximum intrathoracic diameter chest xray No constitutional ( B ) symptoms diagnosis No 1 extranodal site disease PATIENT CHARACTERISTICS : Age : 16 60 Performance status : Not specify Hematopoietic : Granulocyte count least 2,000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin great 2.5 mg/dL Renal : Creatinine great 2 mg/dL Other : No medical condition would preclude study therapy HIV negative No prior malignancy except basal cell skin cancer Not pregnant PRIOR CONCURRENT THERAPY : No prior therapy Hodgkin 's disease No concurrent antineoplastic therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2001</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
</DOC>